MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-025-09490-1

Медицинская библиотека · Scientific reports · 2025

Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment.

Chen Junchen, Huang Shunqiu, Chen Yashi, Luo Cheng, Li Yong

СтатьяМетаанализСистематический обзорПеревод пока не подготовлен

Аннотация

Migraine significantly impacts quality of life, with eptinezumab emerging as a promising calcitonin gene-related peptide-targeting therapy. Real-world data and clinical trials are crucial for evaluating its safety and effectiveness comprehensively. This study evaluated its safety using a dual approach: pharmacovigilance analysis of the FDA's Adverse Event Reporting System (FAERS) database (2020-2024) and a systematic review with meta-analysis of clinical trials. FAERS data identified 5,306 adverse event (AE) reports, with "drug ineffective" (ROR = 6.71) and "migraine" (ROR = 67.45) as the strongest signals. Serious adverse events (SAEs) included anaphylactic reactions (ROR = 4.19) and rare events like increased intracranial pressure. Most AEs occurred within the first treatment month. A meta-analysis of six trials (n = 3,148) found no increased overall AE risk versus placebo (RR = 1.02, 95% CI 0.95-1.10) but a higher SAE incidence (RR = 2.87, 95% CI 1.27-6.48). Upper respiratory infections were more frequent (RR = 1.49, P = 0.04), while dizziness, nausea, and fatigue showed no significant differences. Eptinezumab shows promise but warrants further research on safety in vulnerable populations and real-world settings.

Для цитирования: Chen Junchen, Huang Shunqiu, Chen Yashi, Luo Cheng, Li Yong. Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment.. Scientific reports. 2025. DOI: 10.1038/s41598-025-09490-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.